Literature DB >> 27747066

Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?

Andrew R Kompa1.   

Abstract

Entities:  

Year:  2016        PMID： 27747066      PMCID： PMC5059343          DOI： 10.21037/jtd.2016.07.94

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

Review 2.  New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.

Authors:  Eva Denise Martin; Gian Felice De Nicola; Michael S Marber
Journal:  Circulation       Date:  2012-07-17       Impact factor: 29.690

Review 3.  Inflammation and its resolution as determinants of acute coronary syndromes.

Authors:  Peter Libby; Ira Tabas; Gabrielle Fredman; Edward A Fisher
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

4.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion.

Authors:  X L Ma; S Kumar; F Gao; C S Louden; B L Lopez; T A Christopher; C Wang; J C Lee; G Z Feuerstein; T L Yue
Journal:  Circulation       Date:  1999-04-06       Impact factor: 29.690

Review 5.  The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.

Authors:  Michael S Marber; Beth Rose; Yibin Wang
Journal:  J Mol Cell Cardiol       Date:  2010-11-06       Impact factor: 5.000

Review 6.  C-reactive protein and other inflammatory risk markers in acute coronary syndromes.

Authors:  Gavin J Blake; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

7.  p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.

Authors:  Fiona See; Walter Thomas; Kerrie Way; Alex Tzanidis; Andrew Kompa; Dion Lewis; Silviu Itescu; Henry Krum
Journal:  J Am Coll Cardiol       Date:  2004-10-19       Impact factor: 24.094

8.  Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.

Authors:  A R Kompa; F See; D A Lewis; A Adrahtas; D M Cantwell; B H Wang; H Krum
Journal:  J Pharmacol Exp Ther       Date:  2008-03-11       Impact factor: 4.030

Review 9.  Successful structure-based design of recent p38 MAP kinase inhibitors.

Authors:  Solveigh C Karcher; Stefan A Laufer
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

Authors:  Michelle L O'Donoghue; Ruchira Glaser; Matthew A Cavender; Philip E Aylward; Marc P Bonaca; Andrzej Budaj; Richard Y Davies; Mikael Dellborg; Keith A A Fox; Jorge Antonio T Gutierrez; Christian Hamm; Robert G Kiss; František Kovar; Julia F Kuder; Kyung Ah Im; John J Lepore; Jose L Lopez-Sendon; Ton Oude Ophuis; Alexandr Parkhomenko; Jennifer B Shannon; Jindrich Spinar; Jean-Francois Tanguay; Mikhail Ruda; P Gabriel Steg; Pierre Theroux; Stephen D Wiviott; Ian Laws; Marc S Sabatine; David A Morrow
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272
View more
  3 in total

1.  SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1.

Authors:  Margit Schwartz; Sabine Böckmann; Philipp Borchert; Burkhard Hinz
Journal:  Oncotarget       Date:  2018-05-01

2.  Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-β signaling results in variable activation of human dermal fibroblasts.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Int J Mol Med       Date:  2018-10-23       Impact factor: 4.101

Review 3.  Involvement of p38 MAPK in Synaptic Function and Dysfunction.

Authors:  Chiara Falcicchia; Francesca Tozzi; Ottavio Arancio; Daniel Martin Watterson; Nicola Origlia
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.